litlas
Log inCreate account

Rüdiger Hehlmann

Active 1988–2025

Also published as
Rȕdiger Hehlmann
105
Papers
21,041
Citations
82
h-index
102
i10-index

Citations

Citations per year for Rüdiger Hehlmann1979: 13 citations1989: 1 citations1990: 4 citations1991: 7 citations1993: 3 citations1994: 5 citations1995: 7 citations1996: 20 citations1997: 13 citations1998: 27 citations1999: 51 citations2000: 51 citations2001: 53 citations2002: 75 citations2003: 157 citations2004: 89 citations2005: 114 citations2006: 139 citations2007: 162 citations2008: 128 citations2009: 139 citations2010: 119 citations2011: 157 citations2012: 150 citations2013: 158 citations2014: 159 citations2015: 160 citations2016: 159 citations2017: 126 citations2018: 94 citations2019: 384 citations2020: 439 citations2021: 401 citations2022: 217 citations2023: 144 citations2024: 315 citations2025: 100 citations1980–1988: no citations, so these years are not shown1992: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,100 citing papers, 20.9% of this breakdownGermany: 569 citing papers, 10.8% of this breakdownItaly: 471 citing papers, 8.9% of this breakdownUnited Kingdom: 376 citing papers, 7.1% of this breakdownFrance: 317 citing papers, 6% of this breakdownChina: 187 citing papers, 3.6% of this breakdownAustralia: 176 citing papers, 3.3% of this breakdownSpain: 175 citing papers, 3.3% of this breakdownSwitzerland: 150 citing papers, 2.8% of this breakdownCanada: 133 citing papers, 2.5% of this breakdownNetherlands: 129 citing papers, 2.5% of this breakdownJapan: 115 citing papers, 2.2% of this breakdown
0%20.9%Other 26.1%

Institutions

Fields

  • Medicine77.8%
  • Biochemistry, Genetics and Molecular Biology11%
  • Agricultural and Biological Sciences5.6%
  • Immunology and Microbiology2.5%
  • Computer Science0.7%
  • Chemistry0.4%
  • Other2%

Topics

  • Chronic Myeloid Leukemia Treatments15.5%
  • Eosinophilic Disorders and Syndromes10.1%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment8.2%
  • Chronic Lymphocytic Leukemia Research7.9%
  • Acute Myeloid Leukemia Research7.9%
  • Acute Lymphoblastic Leukemia research2.7%
  • Other47.7%

Coauthors

All papers

Open in search
  1. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

    Authors: Tiziano Barbui, Ayalew Tefferi, Alessandro M. Vannucchi, Francesco Passamonti, Richard T. Silver, Ronald Hoffman, Srđan Verstovšek, Ruben A. Mesa, Jean‐Jacques Kiladjian, Rȕdiger Hehlmann, Andreas Reiter, Francisco Cervantes, Claire Harrison, Mary Frances Mc Mullin, Hans Carl Hasselbalch, Steffen Koschmieder, Monia Marchetti, Andrea Bacigalupo, Guido Finazzi, Nicolaus Kröger, Martin Grießhammer, Gunnar Birgegård, Giovanni Barosi - Leukemia 2018 cited by 552

  2. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

    Authors: for the SAKK and the German CML Study Group, Rüdiger Hehlmann, Michael Lauseker, Susanne Saußele, Markus Pfirrmann, Stefan W. Krause, Hans‐Jochem Kolb, Andreas Neubauer, Dieter K. Hossfeld, C. Nerl, Aloïs Gratwohl, Gabriela M. Baerlocher, Dominik Heim, Tim H. Brümmendorf, Alice Fabarius, Claudia Haferlach, Brigitte Schlegelberger, Marcus Müller, Sabine Jeromin, Ulrike Proetel, Katharina Kohlbrenner, Astghik Voskanyan, Sébastien Rinaldetti, Wolfgang Seifarth, Birgit Spieß, Leopold Balleisen, M-E Goebeler, Mathias Hänel, Anthony D. Ho, Jolanta Dengler, Christiane Falge, Lothar Kanz, Stephan Kremers, Andreas Burchert, Michael Kneba, Frank Stegelmann, Claus-Henning Köhne, H. W. Lindemann, Cornelius F. Waller, M. Pfreundschuh, Karsten Spiekermann, Wolfgang E. Berdel, Lothar Müller, Matthias Edinger, Jiřı́ Mayer, Dietrich W. Beelen, Martin Bentz, Hartmut Link, Bernd Hertenstein, Roland J. Fuchs, Martin Wernli, Frank Schlegel, Rudolf Schlag, Maike de Wit, Lorenz Trümper, Holger Hebart, Markus Hahn, Jörg Thomalla, Christof Scheid, Philippe Schafhausen, Walter Verbeek, Michael J. Eckart, W. Gaßmann, Antonio Pezzutto, Michael Schenk, Peter Brossart, Thomas Geer, Stephan Bildat, E. Schäfer, Andreas Hochhaus, Joerg Hasford - Leukemia 2017 cited by 339

  3. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Authors: Michele Baccarani, Michael Deininger, Gianantonio Rosti, Andreas Hochhaus, Simona Soverini, Jane F. Apperley, Francisco Cervantes, Richard E. Clark, Jörge E. Cortes, François Guilhot, Henrik Hjorth‐Hansen, Timothy P. Hughes, Hagop M. Kantarjian, Dong‐Wook Kim, Richard A. Larson, Jeffrey H. Lipton, François-Xavier Mahon, Giovanni Martinelli, Jiřı́ Mayer, Martin Müller, Dietger Niederwieser, Fabrizio Pane, Jerald P. Radich, Philippe Rousselot, Giuseppe Saglio, Susanne Saußele, Charles A. Schiffer, Richard T. Silver, Bengt Simonsson, Juan-Luis Steegmann, John M. Goldman, Rüdiger Hehlmann - Blood 2013 cited by 1,989

  4. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia

    Authors: Nicholas C.P. Cross, Thomas Ernst, Susan Branford, Jean‐Michel Cayuela, Michael W. Deininger, Alice Fabarius, Dennis Dong Hwan Kim, Kateřina Machová Poláková, Jerald P. Radich, Rüdiger Hehlmann, Andreas Hochhaus, Jane F. Apperley, Simona Soverini - Leukemia 2023 cited by 103

  5. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations

    Authors: Monia Marchetti, Alessandro Maria Vannucchi, Martin Griesshammer, Claire Harrison, Steffen Koschmieder, Heinz Gisslinger, Alberto Álvarez-Larrán, Valerio De Stefano, Paola Guglielmelli, Francesca Palandri, Francesco Passamonti, Giovanni Barosi, Richard T Silver, Rüdiger Hehlmann, Jean-Jacques Kiladjian, Tiziano Barbui - The Lancet Haematology 2022 cited by 113

  6. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

    Authors: Markus Pfirrmann, Michele Baccarani, Susanne Saußele, Joëlle Guilhot, Francisco Cervantes, G.J. Ossenkoppele, Verena Hoffmann, Fausto Castagnetti, Joerg Hasford, Rüdiger Hehlmann, Bengt Simonsson - Leukemia 2015 cited by 300

  7. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

    Authors: Verena Hoffmann, Michele Baccarani, Joerg Hasford, Doris Lindoerfer, Sonja Burgstaller, Dubravka Sertić, Paul Costeas, Jiřı́ Mayer, Karel Indrák, Hele Everaus, Perttu Koskenvesa, Joëlle Guilhot, G. Schubert-Fritschle, Fausto Castagnetti, Francesco Di Raimondo, Sandra Lejniece, Laimonas Griškevičius, Noortje Thielen, Tomasz Sacha, Andrzej Hellmann, Anna Turkina, Andrey Zaritskey, Andrija Bogdanović, Zuzana Sninská, Irena Zupan, Steegmann Jl, Bengt Simonsson, Richard E. Clark, A. Covelli, Gian Cesare Guidi, Rüdiger Hehlmann - Leukemia 2015 cited by 255

  8. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both

    Authors: Steffen Koschmieder, Tariq I. Mughal, Hans Carl Hasselbalch, Giovanni Barosi, Peter Valent, J-J Kiladjian, Georg Jeryczynski, Heinz Gisslinger, Jonas S. Jutzi, Heike L. Pahl, Rüdiger Hehlmann, Alessandro M. Vannucchi, Francisco Cervantes, Richard T. Silver, Tiziano Barbui - Leukemia 2016 cited by 167

  9. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Authors: Michele Baccarani, Jörge E. Cortes, Fabrizio Pane, Dietger Niederwieser, Giuseppe Saglio, Jane F. Apperley, Francisco Cervantes, Michael W. Deininger, Aloïs Gratwohl, François Guilhot, Andreas Hochhaus, Mary M. Horowitz, Timothy P. Hughes, Hagop M. Kantarjian, Richard A. Larson, Jerald P. Radich, Bengt Simonsson, Richard T. Silver, John M. Goldman, Rüdiger Hehlmann - Journal of Clinical Oncology 2009 cited by 1,298

  10. Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

    Authors: Tiziano Barbui, Giovanni Barosi, Gunnar Birgegård, Francisco Cervantes, Guido Finazzi, Martin Grießhammer, Claire Harrison, Hans Carl Hasselbalch, Rüdiger Hehlmann, Ronald Hoffman, Jean‐Jacques Kiladjian, Nicolaus Kröger, Ruben A. Mesa, Mary Frances McMullin, Animesh Pardanani, Francesco Passamonti, Alessandro M. Vannucchi, Andreas Reiter, Richard T. Silver, Srđan Verstovšek, Ayalew Tefferi - Journal of Clinical Oncology 2011 cited by 834

  11. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

    Authors: Markus Pfirrmann, Richard E. Clark, Witold Prejzner, Michael Lauseker, Michele Baccarani, Susanne Saußele, François Guilhot, Sonja Heibl, Rüdiger Hehlmann, Edgar Faber, Anna Turkina, Gert J. Ossenkoppele, Martin Höglund, Andrey Zaritskey, Laimonas Griškevičius, Ulla Olsson‐Strömberg, Hele Everaus, Perttu Koskenvesa, Boris Labar, Tomasz Sacha, Daniela Žáčková, Francisco Cervantes, Adriana Coliță, Irena Zupan, Andrija Bogdanović, Fausto Castagnetti, Joëlle Guilhot, Joerg Hasford, Andreas Hochhaus, Verena Hoffmann - Leukemia 2020 cited by 95

  12. High-risk additional chromosomal abnormalities at low blast counts herald death by CML

    Authors: Rüdiger Hehlmann, Astghik Voskanyan, Michael Lauseker, Markus Pfirrmann, Lida Kalmanti, Sébastien Rinaldetti, Katharina Kohlbrenner, Claudia Haferlach, Brigitte Schlegelberger, Alice Fabarius, Wolfgang Seifarth, Birgit Spieß, Patrick Wuchter, Stefan W. Krause, Hans‐Jochem Kolb, Andreas Neubauer, Dieter K. Hossfeld, Christoph Nerl, Aloïs Gratwohl, Gabriela M. Baerlocher, Andreas Burchert, Tim H. Brümmendorf, Jörg Hasford, Andreas Hochhaus, Susanne Saußele, Michele Baccarani, for the SAKK and the German CML Study Group, Ludwig Fischer von Weikersthal, Markus Hahn, Günter Schlimok, Dietmar Reichert, Jan Janßen, Uwe M. Martens, Peter Majunke, Peter Reichert, Kai Neben, Stefan Korsten, Ch. Scholz, Bernd Oldenkott, Jörg Heßling, D. Kingreen, Christian Sperling, C. Schelenz, I. W. Blau, A. Urmersbach, W. D. Ludwig, Philipp le Coutre, R. Arnold, Maike de Wit, Antonio Pezzutto, E. Schäfer, Roland Schroers, A. Lochter, Dirk Behringer, Y. Ko, St. Weidenhöfer, Walter Verbeek, Peter Brossart, Guido Trenn, W Pommerien, J. Krauter, G. Döering, H. Munzinger, C. Diekmann, Bernd Hertenstein, Sebastian Stier, F. Möller-Faßbender, Mathias Hänel, T. Zöller, C. Lamberti, Babette Koch, A. Henzel, Siegfried Wagner, A. Schmalenbach, M. Hoffknecht, Gerhard Ehninger, Alexander Kiani, Thomas Illmer, Carlo Aul, Michael Flaßhove, F. Henneke, M. Simon, Lothar Müller, Heiko Becker, R. F. Janz, Michael J. Eckart, Roland J. Fuchs, Frank Schlegel, Mohammad Amen Wattad, R. Rudolph, Dietrich W. Beelen, A Lindemann, D. Linck, Wassman, Elke Jäger, Salah‐Eddin Al‐Batran, T Reiber, Cornelius F. Waller, Heinz‐Gert Hoeffkes, L.S. Schulz and 154 more - Leukemia 2020 cited by 92

  13. Survival with chronic myeloid leukaemia after failing milestones

    Authors: Michael Lauseker, Rüdiger Hehlmann, Andreas Hochhaus, Susanne Saußele - Leukemia 2023 cited by 33

  14. Human Endogenous Retrovirus Expression Profiles in Samples from Brains of Patients with Schizophrenia and Bipolar Disorders

    Authors: Oliver Frank, Michelle Giehl, Chun Zheng, Rüdiger Hehlmann, Christine Leib‐Mösch, Wolfgang Seifarth - Journal of Virology 2005 cited by 175

  15. A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group

    Authors: Joerg Hasford, Markus Pfirrmann, Rüdiger Hehlmann, N. C. Allan, Michele Baccarani, Johanna C. Kluin-Nelemans, G. Alimena, Juan Luis Steegmann, Hassan Ansari - JNCI Journal of the National Cancer Institute 1998 cited by 820

  16. Chronic myeloid leukaemia

    Authors: Rüdiger Hehlmann, Andreas Hochhaus, Michele Baccarani - The Lancet 2007 cited by 504

  17. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

    Authors: Joerg Hasford, Michele Baccarani, Verena Hoffmann, Joëlle Guilhot, Susanne Saußele, Gianantonio Rosti, François Guilhot, Kimmo Porkka, Gert J. Ossenkoppele, Doris Lindoerfer, Bengt Simonsson, Markus Pfirrmann, Rüdiger Hehlmann - Blood 2011 cited by 497

  18. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

    Authors: Alice Fabarius, Armin Leitner, Andreas Hochhaus, Martin C. Müller, Benjamin Hanfstein, Claudia Haferlach, Gudrun Göhring, Brigitte Schlegelberger, Martine Jotterand, Andreas Reiter, Susanne Jung-Munkwitz, Ulrike Proetel, Juliana Schwaab, Wolf‐Karsten Hofmann, Jörg Schubert, Hermann Einsele, Anthony D. Ho, Christiane Falge, Lothar Kanz, Andreas Neubauer, Michael Kneba, Frank Stegelmann, Michael Pfreundschuh, Cornelius F. Waller, Karsten Spiekermann, Gabriela M. Baerlocher, Michael Lauseker, Markus Pfirrmann, Joerg Hasford, Susanne Saußele, Rüdiger Hehlmann, for the Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group - Blood 2011 cited by 290

  19. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

    Authors: Andreas Hochhaus, Sebastian Kreil, A. Corbin, Paul La Rosée, MC Müller, Tanja Lahaye, Benjamin Hanfstein, Claudia Schoch, NCP Cross, Ute Berger, Harald Gschaidmeier, Brian Druker, Rüdiger Hehlmann - Leukemia 2002 cited by 905

  20. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

    Authors: Benjamin Hanfstein, Marc Müller, Rüdiger Hehlmann, Philipp Erben, Michael Lauseker, Alice Fabarius, Susanne Schnittger, Claudia Haferlach, Gudrun Göhring, Ulrike Proetel, H-J Kolb, Stefan W. Krause, W.‐K. Hofmann, Jörg Schubert, Hermann Einsele, Jolanta Dengler, Mathias Hänel, Christiane Falge, Lothar Kanz, Andreas Neubauer, Michael Kneba, Frank Stegelmann, Michael Pfreundschuh, Cornelius F. Waller, Susan Branford, Timothy P. Hughes, Karsten Spiekermann, Gabriela M. Baerlocher, Markus Pfirrmann, Joerg Hasford, Susanne Saußele, Andreas Hochhaus, for the SAKK and the German CML Study Group - Leukemia 2012 cited by 417

  21. Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

    Authors: Rüdiger Hehlmann, Martin C. Müller, Michael Lauseker, Benjamin Hanfstein, Alice Fabarius, Annette Schreiber, Ulrike Proetel, Nadine Pletsch, Markus Pfirrmann, Claudia Haferlach, Susanne Schnittger, Hermann Einsele, Jolanta Dengler, Christiane Falge, Lothar Kanz, Andreas Neubauer, Michael Kneba, Frank Stegelmann, Michael Pfreundschuh, Cornelius F. Waller, Karsten Spiekermann, Gabriela M. Baerlocher, Gerhard Ehninger, Dominik Heim, H. Heimpel, Christoph Nerl, Stefan W. Krause, Dieter K. Hossfeld, Hans‐Jochem Kolb, Joerg Hasford, Susanne Saußele, Andreas Hochhaus - Journal of Clinical Oncology 2013 cited by 299

  22. How I treat CML blast crisis

    Authors: Rüdiger Hehlmann - Blood 2012 cited by 276

  23. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV

    Authors: Susanne Saußele, Marie-Paloma Krauß, Rüdiger Hehlmann, Michael Lauseker, Ulrike Proetel, Lida Kalmanti, Benjamin Hanfstein, Alice Fabarius, Doris Kraemer, Wolfgang E. Berdel, Martin Bentz, Peter Staib, Maike de Wit, Martin Wernli, Florian Zettl, Holger Hebart, Markus Hahn, Jochen Heymanns, Ingo Schmidt‐Wolf, Norbert Schmitz, Michael J. Eckart, W. Gaßmann, A. Bartholomäus, Antonio Pezzutto, Elisabeth Oppliger Leibundgut, Dominik Heim, Stefan W. Krause, Andreas Burchert, Wolf‐Karsten Hofmann, Joerg Hasford, Andreas Hochhaus, Markus Pfirrmann, Martin C. Müller - Blood 2015 cited by 200

  24. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

    Authors: William V. Padula, Richard A. Larson, Stacie B. Dusetzina, Jane F. Apperley, Rüdiger Hehlmann, Michele Baccarani, Ekkehard Eigendorff, Joëlle Guilhot, François Guilhot, Rüdiger Hehlmann, François‐Xavier Mahon, Giovanni Martinelli, Jiřı́ Mayer, Martin C. Müller, Dietger Niederwieser, Susanne Saußele, Charles A. Schiffer, Richard T. Silver, Bengt Simonsson, Rena M. Conti - JNCI Journal of the National Cancer Institute 2016 cited by 126